2月4日，心通医疗-B(02160)盘中上涨5.13%，截至14:01，报0.82元/股，成交100.0万元。
心通医疗是一家中国领先的医疗器械企业，主要从事结构性心脏病领域的经导管和手术解决方案的研发和商业化，产品包括VitaFlow系列经导管主动脉瓣植入(TAVI)产品、经导管二尖瓣治疗产品、经导管三尖瓣治疗产品、外科瓣膜产品和手术配件等。目前，该公司的产品已进入中国近500家核心医院，并在阿根廷、泰国、哥伦比亚、巴西等4个国家销售，同时，公司正在全力推进核心产品获得欧盟CE认证，并积极布局印度、韩国、俄罗斯、墨西哥、智利等海外市场。
截至2024年中报，心通医疗-B营业总收入2.23亿元、净利润-5646.1万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.